Australia's most trusted
source of pharma news
Tuesday, 13 January 2026
Posted 12 January 2026 PM
After being named as Novo Nordisk's next Australian General Manager - then resigning before even starting the job - Enrico Canal Bruland has revealed his next career move, 12,000 kilometres away from Sydney.
The global pharma exec has taken a role with Roche subsidiary Genentech as Head of Cardiovascular, Renal & Metabolism based in San Francisco. The company is working on next-generation treatments for obesity.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.